Literature DB >> 27583305

Increased mitochondrial DNA deletions and copy number in transfusion-dependent thalassemia.

Ashutosh Lal1, Esteban Gomez2, Cassandra Calloway3.   

Abstract

BACKGROUND: Iron overload is the primary cause of morbidity in transfusion-dependent thalassemia. Increase in iron causes mitochondrial dysfunction under experimental conditions, but the occurrence and significance of mitochondrial damage is not understood in patients with thalassemia.
METHODS: Mitochondrial DNA (mtDNA) to nuclear DNA copy number (Mt/N) and frequency of the common 4977-bp mitochondrial deletion (ΔmtDNA4977) were quantified using a quantitative PCR assay on whole blood samples from 38 subjects with thalassemia who were receiving regular transfusions.
RESULTS: Compared with healthy controls, Mt/N and ΔmtDNA4977 frequency were elevated in thalassemia (P = 0.038 and P < 0.001, respectively). ΔmtDNA4977 was increased in the presence of either liver iron concentration > 15 mg/g dry-weight or splenectomy, with the highest levels observed in subjects who had both risk factors (P = 0.003). Myocardial iron (MRI T2* < 20 ms) was present in 0%, 22%, and 46% of subjects with ΔmtDNA4977 frequency < 20, 20-40, and > 40/1 × 107 mtDNA, respectively (P = 0.025). Subjects with Mt/N values below the group median had significantly lower Matsuda insulin sensitivity index (5.76 ± 0.53) compared with the high Mt/N group (9.11 ± 0.95, P = 0.008).
CONCLUSION: Individuals with transfusion-dependent thalassemia demonstrate age-related increase in mtDNA damage in leukocytes. These changes are markedly amplified by splenectomy and are associated with extrahepatic iron deposition. Elevated mtDNA damage in blood cells may predict the risk of iron-associated organ damage in thalassemia.

Entities:  

Year:  2016        PMID: 27583305      PMCID: PMC5003175          DOI: 10.1172/jci.insight.88150

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  48 in total

1.  Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.

Authors:  J B Porter; R D Abeysinghe; L Marshall; R C Hider; S Singh
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

Review 2.  Diabetes and Glucose Metabolism in Thalassemia Major: An Update.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Heba Elsedfy; Alessia Pepe; Christos Kattamis; Mohamed El Kholy; Mohamed Yassin
Journal:  Expert Rev Hematol       Date:  2016-02-12       Impact factor: 2.929

3.  Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells.

Authors:  G Link; A Saada; A Pinson; A M Konijn; C Hershko
Journal:  J Lab Clin Med       Date:  1998-05

4.  Increased protein carbonyl groups in the serum of patients affected by thalassemia major.

Authors:  Domenico Trombetta; Sebastiano Gangemi; Antonella Saija; Paola Lucia Minciullo; Francesco Cimino; Mariateresa Cristani; Silvana Briuglia; Basilia Piraino; Stefania Isola; Carmelo Damiano Salpietro
Journal:  Ann Hematol       Date:  2006-05-06       Impact factor: 3.673

5.  The somatic common deletion in mitochondrial DNA is decreased in schizophrenia.

Authors:  Firoza Mamdani; Brandi Rollins; Ling Morgan; P Adolfo Sequeira; Marquis P Vawter
Journal:  Schizophr Res       Date:  2014-09-28       Impact factor: 4.939

6.  Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis.

Authors:  Yesim Aydinok; Selen Bayraktaroglu; Dilek Yildiz; Hudaver Alper
Journal:  J Pediatr Hematol Oncol       Date:  2011-07       Impact factor: 1.289

Review 7.  Optimizing iron chelation strategies in beta-thalassaemia major.

Authors:  John B Porter
Journal:  Blood Rev       Date:  2009-12       Impact factor: 8.250

8.  A duplex real-time qPCR assay for the quantification of human nuclear and mitochondrial DNA in forensic samples: implications for quantifying DNA in degraded samples.

Authors:  Mark D Timken; Katie L Swango; Cristián Orrego; Martin R Buoncristiani
Journal:  J Forensic Sci       Date:  2005-09       Impact factor: 1.832

9.  Combined chelation therapy with deferasirox and deferoxamine in thalassemia.

Authors:  Ashutosh Lal; John Porter; Nancy Sweeters; Vivian Ng; Patricia Evans; Lynne Neumayr; Gregory Kurio; Paul Harmatz; Elliott Vichinsky
Journal:  Blood Cells Mol Dis       Date:  2012-11-11       Impact factor: 3.039

10.  Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.

Authors:  Patrick B Walter; Eric A Macklin; John Porter; Patricia Evans; Janet L Kwiatkowski; Ellis J Neufeld; Thomas Coates; Patricia J Giardina; Elliott Vichinsky; Nancy Olivieri; Daniele Alberti; Jaymes Holland; Paul Harmatz
Journal:  Haematologica       Date:  2008-05-10       Impact factor: 9.941

View more
  2 in total

1.  The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major.

Authors:  Ayşegül Uğur Kurtoğllu; Belkıs Koçtekin; Erdal Kurtoğlu; Mustafa Yildiz
Journal:  Arch Med Sci       Date:  2018-12-30       Impact factor: 3.318

2.  Daily Oral Supplementation with 60 mg of Elemental Iron for 12 Weeks Alters Blood Mitochondrial DNA Content, but Not Leukocyte Telomere Length in Cambodian Women.

Authors:  Shannon L Steele; Anthony Y Y Hsieh; Izabella Gadawski; Hou Kroeun; Susan I Barr; Angela M Devlin; Hélène C F Côté; Crystal D Karakochuk
Journal:  Nutrients       Date:  2021-05-31       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.